Company (symbol) |
Date filed |
Date comm. |
Shares/Units (M) |
Price |
Shares out (M) |
Lead, other underwriters |
Gross (US$M) |
Post-offering market cap (M) |
|
Initial offerings total: $48.3M |
|||||||||
Alzecure Pharma AB (Huddinge, Sweden; First North Premier)1 |
11/10/18 |
11/12/18 |
14.3S |
SEK14 (US$1.54) |
N/A |
N/A |
$21.90 |
SEK500 |
|
Eton Pharmaceuticals Inc. (Deer Park, Ill.; ETON)2 |
8/15/18 |
11/14/18 |
3.6S |
$6 |
16.9 |
National Securities |
$21.60 |
$101.40 |
|
Tiziana Life Sciences plc (London; TLSA)3 |
8/27/18 |
11/27/18 |
0.44ADS |
$9.90 |
137.1 |
Laidlaw & Co. (UK) |
$4.80 |
$1,357.29 |
|
Number of IPOs in November: 3 Average value of November IPOs: $16.1M Number of IPOs in 2018: 73 Total raised in IPOs in 2018: $8,510.34M Average value of IPOs in 2018: $116.58M | |||||||||
Follow-on offerings total: $966.79M |
|||||||||
Acadia Pharmaceuticals Inc. (San Diego; ACAD)4 |
11/26/18 |
11/29/18 |
18.6S |
$17.00 |
143.6 |
Bofa Merrill Lynch; J.P. Morgan Securities; Goldman Sachs; Cowen; Cantor Fitzgerald; JMP Securities; Needham |
$316.20 |
$2,441.20 |
|
Acelrx Pharmaceuticals Inc. (Redwood City, Calif.; ACRX)5 |
6/14/17 |
11/13/18 |
12.7S |
$3.15 |
74.5 |
Credit Suisse; Jefferies; Cantor; RBC Capital Markets |
$39.99 |
$234.68 |
|
Neos Therapeutics Inc. (Dallas; NEOS)6 |
8/12/16 |
11/6/18 |
17.4S |
$2.30 |
46.4 |
Cantor Fitzgerald; JMP Securities |
$40.00 |
$106.72 |
|
Rocket Pharmaceuticals Inc. (New York; RCKT)7 |
7/5/18 |
11/28/18 |
4.1S |
$15.50 |
44.9 |
Bofa Merrill Lynch; Cowen; Evercore ISI; Oppenheimer; Ladenburg Thalmann |
$63.30 |
$695.95 |
|
Sarepta Therapeutics Inc. (Cambridge, Mass.; SRPT)8 |
2/25/16 |
11/9/18 |
3.81S |
$131.00 |
70.5 |
Goldman Sachs; J.P. Morgan Securities; Credit Suisse |
$500.00 |
$9,235.50 |
|
Sonoma Pharmaceuticals Inc. (Petaluma, Calif.; SNOA) |
11/9/18 |
11/20/18 |
7.3S and W for 3.65S |
$1.00 |
13.9 |
Dawson James Securities |
$7.30 |
$13.90 |
|
Number of follow-ons in November: 6 Average value of November follow-ons: $161.13M Number of follow-ons in 2018: 224 Total raised in follow-ons in 2018: $28,076.76M Average value of follow-ons in 2018: $125.34M | |||||||||
Notes Unless otherwise indicated, shares are traded on the Nasdaq exchange. Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. This chart includes only biopharma companies that develop therapeutics. HKEX = Hong Kong Stock Exchange. 1 Alzecure raised SEK200M (US$21.9M) in its IPO. 2 Eton's overallotment option: 540,000 shares. 3 Tiziana Life Sciences' ADSs each represent 10 ordinary shares. Total raised was £3.42M (US$4.8M). Overallotment option: 66,347 ADSs. 4 Includes Acadia's overallotment option: 2.4M shares. 5 Acelrx's overallotment option: 1.09M shares. 6 Neos Therapeutics' overallotment option: 2.6M shares. 7 Includes Rocket's overallotment option: 532,500 shares. Rocket also is raising an additional $15M through a private placement. 8 Sarepta's overallotment option: 572,500 shares. |